Search This Blog

Friday, November 2, 2018

What it’s like to live with polio-like condition AFM: one little boy’s journey


The diagnosis was in, but Jessica Kulakowski still didn’t have the answers, so she started scouring the internet to find out why her son’s cold had left his right arm virtually lifeless.
Online she found case studies but nothing definitive about why her then-1-year-old boy, Chase, contracted the rare polio-like condition known as acute flaccid myelitis, or AFM. The condition, in the news as a spate of new cases have made headlines in Illinois and beyond, affects mostly children and causes muscles to atrophy, leaving some bedridden with paralysis and unable to breathe on their own. Medical experts have in some cases linked the syndrome to an enterovirus, which causes the common cold and other respiratory illnesses.
Two years after her son’s diagnosis, questions linger for the northwest Indiana mom, who worries anew each time the toddler complains of an ache or has the sniffles: Could this be another complication related to AFM?
“It’s like living in paranoia because there’s just no answer to anything,” Kulakowski said.


Nationwide, the rare condition has gotten more attention after federal health officials reported an increase in cases in recent weeks. They include at least 10 cases diagnosed in Illinois and at least seven in Minnesota, leaving parents like Kulakowski perplexed: How could such a complicated medical journey begin with their little one’s runny nose?
Now 3 years old, Chase races his toy dump trucks through the family’s Dyer, Ind., home, a stark difference from when the paralysis of his right arm caused him to lose his balance. His parents remember the agony of watching him fall as he tried to walk. But a nerve transfer — a procedure that restored movement to his shoulder and elbow — and continued physical therapy has enabled him to use his right arm again, though he continues to build up its strength. In therapy he’s using a bat and knocking things down to strengthen his arm.
“I’m not sure he’s ever going to fully recover from it,” Kulakowski said. “I don’t see it as a realistic outcome. I think he’s always going to know he’s different.”


Paralyzed after nap

Chase’s medical journey started with a runny nose in October 2016 that doctors initially thought was a respiratory infection. Then seemingly over a two-hour nap, Chase’s right arm became paralyzed. He had been under the watch of a baby sitter, but the caretaker only noticed that the boy was tired that day.


David Kulakowski, Chase’s father, knew something was seriously wrong that night while getting his son ready for a bath. He took off his son’s shirt and saw the small arm “just flop.” The father picked up the arm, let it go and watched the lifeless limb fall down. That prompted the couple to take the boy to a nearby urgent care center, where they were told it appeared the boy had AFM.
Skeptical of the quick diagnosis, the couple took the boy to two hospitals for second opinions. Chase spent three days at Lurie Children’s Hospital in Chicago where he underwent an MRI. He was diagnosed and discharged with a list of options for physical therapy.
What Chase was diagnosed with is so rare that the federal Centers for Disease Control and Prevention reports that it affects less than 1 in a million people. Since 2014 there have been 386 confirmed cases of AFM. While the condition itself isn’t believed to be contagious, the viruses that may lead to AFM are. On its website, the CDC explains that nonpolio enteroviruses — which normally don’t make people sick, and if they do, it’s often the common cold — can cause AFM.
Jessica Kulakowski found support in an online community of parents seeking answers about the condition. Chase had been around other children who probably got the same virus. Yet he was the only one who developed AFM.
“Why it continued to his spinal cord? They don’t know,” she said. “That’s the one thing they can’t answer, and here we are two years later and still nobody can answer it.”
Because one exact cause is not known, health officials have looked into possible clues in everything from viruses to environmental toxins to genetic disorders. Some AFM cases have been connected to a severe respiratory illness caused by enterovirus D68, but Chase tested negative for it, his mother said.
AFM happens when a virus travels to a person’s spinal cord, affecting the specific area that correlates with the person’s muscles. Chase didn’t show the most severe symptoms other children have shown, such as being unable to swallow or breathe. Some children start to show signs of weakness after a prolonged cold. Other warning signs include eyelid or facial dropping and difficulty moving the eyes.


Chase’s ‘batteries’

There is no cure for AFM, but doctors can provide supportive care to patients including physical and occupational therapy. Then the parents started to hear about nerve transfers to restore movement in the paralyzed limbs. A private Facebook group of parents dealing with AFM led the family last December to Shriners Hospitals for Children-Philadelphia for a nerve transfer.
Doctors moved nerves from Chase’s rib area — which were considered redundant because they perform the same function as other nerves — to his shoulder and elbow where the nerves weren’t working. The process is really reconnecting a person’s brain to the muscles, said Dr. Dan Zlotolow, an orthopedic hand surgeon who operated on Chase. The results are more promising the younger the patient is and the sooner it happens after the initial injury, Zlotolow said.
In Philadelphia, doctors have done nerve transfers in 16 children with AFM who had paralysis in their hand, arm or shoulder, Zlotolow said. Other doctors across the country have focused on doing the procedures on AFM patients with paralysis in the legs.
In the 16 cases, the children have regained movement, but building up the strength of the muscles will take time, Zlotolow said.


The nerve transfer was an hourslong procedure that was explained to Chase by telling him that doctors were going to try to make his arm work again, Jessica Kulakowski said.
“And he said, ‘Oh, he’s going to put batteries in there,’” she remembers her son saying. She commemorated the date of the surgery by getting a tattoo of batteries on her back.

Uptick in cases

The family made the drive back to Indiana from Philadelphia with Chase and a Spider-Man doll in identical bright-red casts. As his parents took care of Chase, the toddler took care of Spider-Man, making sure they took their medicine together. Three months after surgery, Chase was able to lift his arm and move his elbow with support from his father. Since then he’s continued therapy. He’s working on picking things up, and he tends to default to his left arm now to do things like toss a ball.


When Chase was first diagnosed, it was part of a wave of cases that were reported nationally from August to October 2016. The CDC is again seeing a rise in cases similar to increases in 2016 and 2014, but officials don’t know why more people are getting AFM every other year. The spikes tend to occur from August to October.
Dr. Nancy Messonnier, of the CDC, said in a recent conference call that there have been 62 confirmed cases — the majority involve minors — so far this year in 22 states. There are an additional 127 suspected cases of AFM that officials are further investigating. The CDC began tracking the cases in 2014 when it first started to see a bubble of cases.
Messonnier said the condition is rare, and doctors have been relying on an assessment of symptoms and MRI results to make an AFM diagnosis. The CDC investigates outbreaks of illnesses across the country by gathering information from state health officials, doing laboratory testing and by consulting medical experts, Messonnier said. Health officials still can’t pinpoint whether anyone in particular is more at risk or even why that person would be more likely to get it.
“There is a lot we don’t know about AFM, and I’m frustrated that despite all our efforts we haven’t been able to identify the cause of this mystery illness,” Messonnier said.
Though the condition has been compared with polio, the CDC reports that polio is not the cause of AFM, Messonnier said.
Jessica Kulakowski said she and other parents have been using the increase in cases to get the word out about the need for more research and resources. Her son was featured in a recently created Instagram account that features children with AFM. Among the hashtags used under a photo collage of Chase was #WENEEDRESEARCH.
The increase also means parents are now coming to her with questions. She still doesn’t have many answers.
“What are we supposed to do for our kids if nobody has any idea?” she said.

Insulin drugmakers under scrutiny for pricing, patent practices


  • Insulin drugmakers face new criticism for their pricing and use of patents on diabetes treatments, as two reports released Thursday by the largest bipartisan Congressional caucus and a pharma-focused consumer group shined a light on the pharma companies’ business practices.
  • In a report on the insulin market, Congressional Diabetes Caucus co-chairs attacked the current system as “unfairly putting insulin out of reach, placing millions of lives at risk.” Their report makes 11 policy recommendations for Congress, ranging from encouraging value-based contracts to requiring more disclosure on rebates and list prices to addressing patent extensions.
  • The Initiative for Medicine, Access and Knowledge, meanwhile, unveiled an analysis of the patents protecting Sanofi’s top-selling diabetes treatment Lantus, finding nearly all of patent applications for the drug were filed by the French pharma after it was approved.

These reports hint at what could be a coming battle for U.S. lawmakers in regulating drugmakers and combating rising drug pricing, particularly as political experts and polls suggest the U.S. House of Representatives could flip to Democratic control and leadership following the Nov. 6 midterm elections.
Democrats have made healthcare a focal point going into next week’s elections, and going after the pharmaceutical industry has a level of bi-partisan support that other healthcare issues, particularly insurance reform, lack.
And now, the Congressional Diabetes Caucus, with more than 290 congressional members from both parties, is stepping up criticism on insulin drugmakers in particular, advocating reforms on pricing and formularies among other policies.
Eli Lilly, Novo Nordisk and Sanofi control much of the market for insulin, which remains a lucrative market despite growing pricing pressures from payers in the U.S.
The report from I-MAK highlights how aggressive patenting, at least for Sanofi’s Lantus (insulin glargine), may be playing a role in keeping insulin prices high.
Lantus was among the world’s best-selling drugs last year, posting more than $5 billion in worldwide sales. Through the first nine months of 2018, the diabetes drug notched roughly $3.1 billion in sales.
Sanofi filed its first Lantus patent in 1994, and the Food and Drug Administration approved the drug in 2000. I-MAK found 69 of its 74 U.S. patent applications, or about 93%, were filed after the drug was approved and launched. The original patent expired in 2015.
These have extended Lantus’ patent protection to 2031, the report stated, protecting it from generic or biosimilar competition in the meantime. (Sanofi said in its 2017 annual report that its Lantus patents expire in March 2028).
While multiple Lantus biosimilars are available in Europe and Japan, only one copycat rival has launched in the U.S.: Eli Lilly’s Basaglar (insulin glargine), which was approved in December 2016 as a follow-on biologic.

Merck rolls RotaTeq in China, phasing out a discounted Africa supply deal


When supplies are strained, what gives? For Merck & Co., in the midst of global production constraints, it’s phasing out shipments of cut-rate RotaTeq doses to Africa while pushing its China launch through a local partner.
Merck inked a deal with the nonprofit group Gavi to supply RotaTeq, a lifesaving rotavirus vaccine, to four low-income countries at a big discount. But now that its Chinese partner is rolling out the vaccine in that market, supplies won’t stretch to meet all that demand.
The company can now only ship two-thirds of the promised doses to Burkina Faso, Mali, Cote d’Ivoire and Sao Tome this year and next, Gavi said. It will stop distributing the vaccine to those countries altogether in 2020, according to NPR. More than half a million children could miss out on vaccinations due to the shortfall, according to Gavi.
“Merck’s reduction in rotavirus vaccine supply to Gavi-supported countries means countries affected will now urgently need to find an alternative,” Gavi CEO Seth Berkley said in a statement. It’s “deeply disappointing news and in the short term will mean that children are likely to miss out on this lifesaving vaccine, leaving them vulnerable to this horrific disease,” he added.
The development comes after Merck’s vaccine won approval in China this April. The Big Pharma is selling its vaccines there through partner Chongqing Zhifei Biological Products Co., and that company said it plans (PDF—Chinese) to buy more than $450 million worth of RotaTeq doses through 2021. According to NPR, doses in China carry a significantly higher price than Merck’s agreed-upon cost for Gavi.
A Merck representative said vaccine makers have been dealing with increased demand in recent years, and while the company is “increasing our manufacturing capacity, including building new sites, creating that additional capacity is a multi-year process.”
She said Merck is “committed to saving and improving lives around the world with our vaccines, and we are working closely with our customers around the world, including UNICEF and GAVI, to meet the unprecedented increase in global demand for vaccines, including for rotavirus.”
GlaxoSmithKline, for its part, continues to distribute rotavirus vaccine doses to Gavi. The company supplies 90% of Gavi countries’ demands for rotavirus vaccines, but is also dealing with supply constraints, the nonprofit said. GSK can provide its vaccine to countries already running rotavirus vaccination campaigns, but won’t be able to support new campaigns this year or next.
Meanwhile, the World Health Organization recently prequalified inexpensive rotavirus vaccines from Bharat Biotech and Serum Institute of India. Those companies—both based in India—have said they can meet demand starting in 2020, but the switch to newer vaccines will result in costs and delays, Gavi said.
While both of those companies’ prequalifications mark progress in global efforts to increase access to rotavirus vaccines, an expert with Seattle-based nonprofit PATH told NPR it will take at least two years to make the vaccines available in West Africa. During that delay, millions of babies there will be at risk, Johns Hopkins University professor of pediatrics and pediatric infectious diseases Dr. Mathuram Santosham told the radio network.

As of the end of 2017, Gavi funded rotavirus vaccinations in 43 countries and for 76 million children, according to the group.
Merck’s RotaTeq brought in $540 million in sales through the first three quarters of 2018, a slight increase over $525 million during the first nine months of 2017.
Merck is also in the process of launching its HPV vaccine Gardasil 9 in China after an approval in April. That launch is also underway through local distributor Chongqing Zhifei Biological Products Co.

Celgene up for $600M Revlimid boost as Rituxan combo scores in lymphoma


Celgene’s Revlimid may have slipped in tandem with Roche’s Rituxan in previously untreated follicular lymphoma patients. But in the second-line setting, the drug has a win.
Thursday, detailed results from the phase 3 Augment study—which looked at the combo, known as R2 for short, in relapsed and refractory FL patients—hit the American Society of Hematology website in advance of the group’s annual meeting in December. And they showed big-time benefits for the regimen over solo Rituxan.
Patients in the R2 arm went a median 39 months without their cancer worsening versus just 14 months for patients in the Rituxan-only arm. In other words, the pairing reduced the risk of disease progression or death by 54%. More patients responded to therapy in the R2 group, too, with 78% responding compared with Rituxan’s 34%.
The data impressed Leerink Partner analyst Geoffrey Porges, for one, who wrote to investors previously that a 24-month progression-free survival mark would be “very positive.” With the 39-month benefit, “Revlimid use in the 2L follicular lymphoma setting should increase,” he wrote Thursday to clients, adding that the result “suggests Revlimid’s use should go beyond the unfit/elderly population that is often addressed” by Rituxan.
There’s more good news: R2’s performance in the setting “appears to be superior” to what’s expected from immunotherapy-chemo combos in the same patient group “based on historical results,” Porges wrote, which means Celgene may not have to fret much about forthcoming competition. All things considered, Porges expects the new data to drive an additional $600 million in yearly revenue for the drug.

Celgene will certainly take it, especially with biosimilar rivals to its key moneymaker advancing. The New Jersey biotech has been working to drum up additional revenue opportunities for its superstar, but in follicular lymphoma, it hit a stumbling block last December when R2 failed to stave off cancer progression against a Rituxan-chemo marriage.

Shire’s Takhzyro gets off to hot start, boosting sales ahead of Takeda buyout


Critics of Takeda’s $62 billion Shire buyout and Shire’s own investors have fretted lately about the company’s standing in the hemophilia market. But immunology is a different story.
In the third quarter, the unit continued to post “strong growth,” as Jefferies analyst David Steinberg put it in a Thursday note to clients, with revenues checking in at $1.2 billion. The division now represents nearly one-third of the Dublin drugmaker’s business, and that figure could grow if new launcher Takhzyro keeps up its early pace.
After snagging an August FDA approval, the drug—which Steinberg has called a “best-in-class” prospect in hereditary angioedema—racked up $51 million in quarterly sales.
“While still early, we are encouraged by the response to the U.S. launch. Patients are coming from existing prophylaxis therapies, as well as patients new to prophylaxis,” Shire CEO Flemming Ornskov told investors on the biotech’s third-quarter conference call, adding, “We have seen physicians prescribe Takhzyro who have not previously prescribed” fellow Shire HAE-fighter Cynrize.
One reason for the strong early uptake? The company’s Quick Start program, which is “enabling patients to start on therapy now while we engage with payers on their formulary updates,” Ornskov noted. And he’s “very positive” about what he’s seen “in just a few months” on the reimbursement side, he said, suggesting that ultimately snagging reimbursement for those Quick Start patients won’t be a major issue.

Of course, Shire is hoping Takhzyro will step up its immunology sales outside the U.S., too, and that’s where Steinberg sees a big opportunity. Shire “has been unable to aggressively promote prophylaxis HAE treatment ex-U.S., given Cinryze supply constraints in recent years,” he wrote.
Meanwhile, Shire’s hematology business—which has been under major scrutiny since the company’s hemophilia-focused Baxalta buy, and even closer judgment since Roche introduced market disrupter Hemlibra—“remains largely stable,” Steinberg said. While Shire’s inhibitor business declined 11% in the third quarter thanks to Hemlibra’s impact, the dip was “manageable,” and Shire’s unit was bolstered by uptake of long-acting hemophilia A drug Adynovate, he added.

Medical Cannabis Products Now Available In The UK


The global cannabis industry took two big steps forward this week.
On Oct. 31, Mexico’s Supreme Court said the laws that ban recreational weed are unconstitutional, essentially opening the door for a potential legalization of pot in the future.
The second major development took place across the pond. The UK government rescheduledcertain cannabis-based products for medicinal use. This allows medical professionals to prescribe products containing cannabis if they consider that patients would benefit from it.

It’s Not Legalization…Yet

Under the new guidance, general practitioners aren’t allowed to prescribe cannabis products, but they can refer patients to specialists that will be able to issue a prescription under the National Health System.
The change is significant because previously, marijuana and all products containing it were considered illegal drugs and access to cannabis-based treatments was available through a special license from the Home Office issued the Home Secretary.
Cannabis products can only be prescribed in a small number of cases such as nausea from chemotherapy, muscle stiffness caused by multiple sclerosis and to children with rare or severe forms of epilepsy.
The U.S. Food and Drug Administration earlier this year approved the first cannabis-based drug in history, Epidiolex, which was developed by UK-based GW Pharmaceuticals plc GWPH 1.05%. Epidiolex is designed for seizures associated with rare forms of epilepsy in children.

Why It’s Important

The legalization of certain cannabis products for certain conditions is important for the UK health system, because it means the UK government has changed its attitude towards marijuana and has recognized its medical benefits.
It also creates more opportunities for companies to get more involved in marijuana and further study its benefits and develop new cannabis-based treatments for other issues.
“Having U.K. patients being able to better access medicinal cannabis is a huge step forward, and a very encouraging sign for a company like Katexco,” said Dr. Jonathan Rothbard, CEO and Chief Science Officer of Katexco, a newly-formed biotech experimenting with CBD to develop anti-inflammatories.
“One of the main motives for the UK’s shift in cannabis policy is that prescribing medical cannabis would allow for safer regulation and generate tax revenue,” said Jessica Billingsley, CEO and Co-Founder of MJ Freeway, leading seed-to-sale technology provider and developer. “As a global technology cannabis company, this could be a great step forward in allowing us to tap into one of the world’s most prominent governments and economies to help with compliance and tracking.”
Michael Klein, CEO of cannabisMD, said “Through steps like this, the medical community will continue to gather important data points and build a holistic view of cannabis as it relates to health and wellness.”

Amarin’s early touting of Vascepa data ahead of detailed results questioned


At the end of September, Amarin teased some early findings for Vascepa, its preventive medicine for people at risk of heart disease. The claim was astounding: a 25% relative risk reduction for deaths related to heart attacks, strokes and other conditions. Headlines proclaimed a potential game changer in treating cardiovascular disease. And company shares quickly soared, from $3 a share to about $20.
Vascepa is Amarin’s only product. The company wants to turn its pill made of purified fish oil into a cash cow, allowing it to staff up both in the United States and abroad so it can sell doctors and millions of consumers on its medical benefits. Although the product has been on the market for more than five years, its first TV ad campaign rolled out this summer in anticipation of the study findings.
Except there is one problem. The particulars of the scientific study on which this claim was based remain a mystery.
Amarin’s preliminary announcement came via a news release on Sept. 24. The company plans to release detailed findings in November at the national American Heart Association conference. Then early next year, it plans to seek FDA approval to use the drug as a preventive for a range of heart conditions, beyond its current role targeting high triglyceride levels.
In the interim, a battle is brewing among physicians, cardiovascular experts and pharma watchers who say Vascepa brings to the foreground troubling trends in the marketing and advertising of new drugs. Companies sometimes promote new products, but withhold the detailed findings until much later. The consequences for both consumers and the health system are vast.

“Until all the data is available for review by the public and medical community, it’s really premature to see some of the cheerleading that’s being done,” said Eric Strong, a hospitalist and clinical assistant professor at Stanford School of Medicine. “It’s harder to change people’s minds once you have these rosy pictures.”
John Thero, Amarin’s CEO, argued that the imminent release of the drug’s complete picture should alleviate those concerns.

In unveiling topline findings in a news release, he said, the company’s playbook doesn’t diverge from that of other pharmaceutical makers, and provides a necessary level of disclosure for shareholders.
But it’s the specifics in the data — for instance, which patients benefited, by how much, their absolute risk reduction and which precise conditions saw improvement — that illustrate whether a product is cost-effective, said medical and drug experts.
That’s especially true in the case of Vascepa, whose manufacturer is working hard to convince people the product is clinically superior to ordinary fish oil supplements. Fish oil, which can retail for a few dollars a bottle, has long been promoted as a preventive for heart disease. But the substance has never held up in clinical trials as a way to systematically lower disease risk, said experts.
That’s where Amarin’s product is superior, Thero said.
The manufacturer has tried to limit competition by seeking to block other fish oil products —arguing to the US International Trade Commission that omega-3 supplements aren’t equivalents, and calling on the FDA to block a chemical component of fish oil, known as EPA and marketed by a number of supplement companies, from being sold as a dietary supplement. Amarin hasn’t yet prevailed.

Preston Mason, a biologist who consults for Amarin and has advocated on its behalf, argued that ordinary fish oil supplements carry risks because they are not regulated or approved by the FDA, which does oversee prescription drugs like Vascepa.
How Vascepa performs against regular fish oil remains unknown. Amarin’s trial compared the drug against a placebo, not over-the-counter supplements.
Vascepa itself isn’t new. It was approved in 2012 as a remedy for extremely high triglyceride levels, which can put patients at risk for pancreatic problems. But reducing that fat hadn’t been conclusively tied to, say, lowering the risk of heart attacks, or other major cardiac problems.
That link, ostensibly, is what Amarin is trying now to assert. And there’s plenty of money to be made if it succeeds.
As of last December, Vascepa retailed for about $280 for a month-long supply, a list price increase of 43% over five years, though the company says its net sale price has stayed the same. (That difference would come if Amarin increased the size of rebates, or discounts it provides, commensurate with price hikes.)
Now, citing the drug’s potentially increased value, Amarin has declined to say whether it will change the price again — though Thero said he sees greater profit potential if the company increases sales volume rather than price.
This gets at the crux of this debate. If a company makes available the technical details of a product, but only after hyping the findings, and if the details undercut some of that buzz — is it too late?

Khurram Nasir, a Yale cardiologist, acknowledged that it’s unclear how effective Vascepa really is, but maintained those ambiguities will be cleared up soon enough.
Khurram Nasir
“As the findings reveal themselves, there will be a lot of discussion around cost effectiveness, and whether this is worth the spend,” Nasir said.
Mason, the Amarin scientist, said FDA scrutiny can also alleviate concerns about overhype.
But others worry the perception of Vascepa’s effectiveness is now set.

“People are weighing in with really strong language, without enough information,” said Lisa Schwartz, who co-directs the Dartmouth Institute’s Center for Medicine and Media and studies effective scientific communication.
That has both clinical and financial consequences, she added. Doctors are more likely to prescribe a product that’s been heavily promoted, even if subsequent discussion indicates the drug isn’t as powerful as initially implied. And manufacturers can cash in, whether through increased company stock market value or by charging higher list prices.
For Vascepa, the central question is which specific heart conditions saw risk reduction, she and others said. In its news release, Amarin noted a “composite outcome” — that is, the 25% relative improvement encompassed all conditions for which the researchers tested.

“People are saying, Wow, it reduced heart attack, stroke and blah, blah, blah — when it may just reduce the least important one,” said Steven Woloshin, Schwartz’s research partner.
Another issue: The Vascepa trial focused on a specific population — patients with high triglyceride levels plus elevated risk of cardiovascular disease or diabetes who were already taking a daily statin. That means any proof of benefit is limited to that group.
Woloshin and Schwartz both suggested that nuance could get lost in translation. “It is this much narrower, high-risk population,” Schwartz said.
Woloshin added, “The fear is [the message] would generalize to anyone with high triglycerides.”
This concern is amplified by a 2016 court settlement in which the FDA permitted Amarin to market Vascepa to audiences for whom it hasn’t been specifically approved — so long as the company doesn’t say anything untrue about the drug.
Thero said Amarin’s marketing of Vascepa has stayed, and will remain, consistent with what is factual and relevant.
“We are proceeding consistently with what the FDA has guided,” he said.
But, some experts said, the 2016 settlement could unlock the door to wider marketing of Vascepa’s off-label use, implying the pill benefits more people than it actually does.

“They’ll take pains to show how different this is from everything out there … and its results in these populations,” said Ameet Sarpatwari, an epidemiologist and lawyer at Harvard Medical School, who studies the pharmaceutical industry. “What they can’t do is say it will be beneficial to these other populations. But they can hint at that.”